Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective

References

• Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia13(5), 606–612 (2007).
   PubMed Web of Science ®Google Scholar
• Poonnoose PM, Srivastava A. Functional assessment of arthropathy – an international perspective. Semin. Hematol.43(1 Suppl. 1), S27–S32 (2006).
   Google Scholar
• Raffini L, Manno C. Modern management of haemophilic arthropathy. Br. J. Haematol.136(6), 777–787 (2007).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Merchan EC. Orthopaedic surgery in persons with haemophilia. Thromb. Haemost.89(1), 34–42 (2003).
   PubMed Web of Science ®Google Scholar
• Sherry DD. Avoiding the impact of musculoskeletal pain on quality of life in children with hemophilia. Orthop. Nurs.27(2), 103–108 (2008).
   PubMedGoogle Scholar
• DiMichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia10(Suppl. 4), 140–145 (2004).
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Plosker GL. Recombinant factor VIIa (eptacog α), a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics25, 1007–1029 (2007).
   PubMed Web of Science ®Google Scholar
• Mariani G, Kroner B; Immune Tolerance Study Group. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica86(11), 1186–1193 (2001).
   PubMed Web of Science ®Google Scholar
• Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica85(Suppl. 10), 15–20 (2000).
   PubMedGoogle Scholar
• Santagostino E, Gringeri A, Mannucci PM. State of care for hemophilia in pediatric patients. Paediatr. Drugs4(3), 149–157 (2002).
   PubMedGoogle Scholar
• Mariani G, Hilgartner M, Thompson AR et al. Immune tolerance to factor VIII: the international registry data. Adv. Exp. Med. Biol.386, 201–208 (1995).
   PubMedGoogle Scholar
• Mathew P. Current opinion on inhibitor treatment options. Semin. Hematol.43(2 Suppl. 4), S8–S13 (2006).
   PubMed Web of Science ®Google Scholar
• Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia12(Suppl. 6), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Hay CRM, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br. J. Haematol.133(6), 591–605 (2006).
   PubMed Web of Science ®Google Scholar
• DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia13(Suppl. 1), 1–22 (2007).
   PubMed Web of Science ®Google Scholar
• Schramm W. Economics of prophylatic treatment. Haemophilia9(Suppl. 1), 111–115 (2003).
   PubMed Web of Science ®Google Scholar
• Roosendaal G, Lafeber F. Prophylatic treatment for prevention of joint disease in hemophilia – cost versus benefit. N. Engl. J. Med.357, 603–605 (2007).
   PubMed Web of Science ®Google Scholar
• NovoSeven®, prescribing information. Novo Nordisk Inc, NSW, Australia (2008).
   Google Scholar
• NovoSeven®, prescribing information. Novo Nordisk Inc, Buenos Aires, Argentina (2010).
   Google Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J. Thromb. Haemost.5(9), 1904–1913 (2007).
   PubMed Web of Science ®Google Scholar
• Knight C, Dan AM, Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv. Ther.26(1), 68–88 (2009).
   PubMedGoogle Scholar
• Treur MJ, Mccracken F, Heeg B et al. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia15(2), 420–436 (2009).
   PubMedGoogle Scholar
• Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia9(4), 521–540 (2003).
   PubMed Web of Science ®Google Scholar
• Odeyemi IAO, Dan AM. Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis. Curr. Med. Res. Opin.25(1), 239–250 (2009).
   PubMed Web of Science ®Google Scholar
• Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr. Med. Res. Opin.22(1), 23–31 (2006).
   PubMed Web of Science ®Google Scholar
• Chang H, Sher GD, Blanchette VS, Teitel JM. The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia5(4), 247–252 (1999).
   PubMed Web of Science ®Google Scholar
• Goudemand J. Treatment of patients with inhibitors: cost issues. Haemophilia5(6), 397–401 (1999).
   PubMed Web of Science ®Google Scholar
• Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia11(Suppl. 1), 11–17 (2005).
   PubMedGoogle Scholar
• Rogoff EG, Guirguis HS, Lipton RA et al. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia. Thromb. Haemost.88(4), 545–553 (2002).
   PubMedGoogle Scholar
• Harper P, Brasser M, Moore L, Teague L, Pitcher L, Ockelford P. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital. NZ Med. J.22(116), 1180 (2003).
   Google Scholar
• Gringeri A, Von MS, Auerswald G et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia10(1), 26–33 (2004).
   PubMed Web of Science ®Google Scholar
• Siboni SM, Mannucci PM, Gringeri A et al. Health status and quality of life of elderly persons with severe haemophilia born before the advent of modern replacement therapy. J. Thromb. Haemost.7(5), 780–786( 2009).
   PubMed Web of Science ®Google Scholar
• Ljung R, Ronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia6(6), 619–624 (2000).
   PubMedGoogle Scholar
• Berntorp E, Lethagen S. The role of home infusion therapy in haemophilia: a disease management perspective. Dis. Manage. Health Outcomes7(2), 77–81 (2000).
   Google Scholar